biojoint reviews
Biojoint is an all-natural supplement with a rate of bioavailability, which shows that the supplement is safe to use for the majority of pets.
BioJoint Reviews – Does This Product Really Work?
We, Health Web Magazine, the owner of this e-commerce website, fully intends to comply with the rules of the Federal Trade Commission (FTC) regarding the use of endorsements, testimonials, and general advertising and marketing content. As a visitor to Health Web Magazine you should be aware that we may receive a fee for any products or services sold through this site.
Content
This content may contain all or some of the following – product information, overviews, product specifications, and buying guides. All content is presented as a nominative product overview and registered trademarks, trademarks, and service-marks that appear on Health Web Magazine belong solely to their respective owners. If you see any content that you deem to be factually inaccurate, we ask that you contact us so we can remedy the situation. By doing so, we can continue to provide information that our readers can rely on for truth and accuracy.
Our Top Selections Box – Promotional Sales
Products shown in the section titled ‘Our Top Products’ are those that we promote as the owner and/ or reseller and does not represent all products currently on the market or companies manufacturing such products. In order to comply fully with FTC guidelines, we would like to make it clear that any and all links featured in this section are sales links; whenever a purchase is made via one of these links we will receive compensation. Health Web Magazine is an independently owned website and all opinions expressed on the site are our own or those of our contributors. Regardless of product sponsor relations, all editorial content found on our site is written and presented without bias or prejudice.
Something we believe is that every page on the website should be created for a purpose. Our Quality Page Score is therefore a measurement of how well a page achieves that purpose. A page’s quality score is not an absolute score however, but rather a score relative to other pages on the website that have a similar purpose. It has nothing to do with any product ratings or rankings. It’s our internal auditing tool to measure the quality of the on the page content. There are a number of factors that determine the Page Score of a given page. Landing page quality is a factor in determining Page Score. Landing page quality generally refers to whether or not the overall page contains relevant and original content to the web page visitor. The content quality value of a web page is determined by comparing a page to known quality patterns and each pattern carries a different weighting in how it affects the overall content quality value of a page. We also factor in user generated feedback on this form plus a page quality algorithm. Since web pages content can change, the content quality value of a web page is updated periodically.
The non-surgical treatments we offer include patient-specific nutrition and exercise programs, individually designed physical therapy that includes biologic components such as restricted blood flow training, and/or platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMC) injections.
Mizzou BioJoint® Center Treatments
We offer surgical and non-surgical treatments to safely and effectively meet each patient’s needs and expectations.
The non-surgical treatments we offer include patient-specific nutrition and exercise programs, individually designed physical therapy that includes biologic components such as restricted blood flow training, and/or platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMC) injections.
The surgeries performed at the Mizzou BioJoint® Center include restorative cartilage, bone, meniscus, ligament and tendon procedures designed to safely improve your joint health and function. Learn more about who is an ideal candidate for surgery at the Mizzou BioJoint® Center.
We evaluate each patient to ensure that we help you understand the options available to treat your joint problem. Learn more by reading our FAQs.
These statements have not been evaluated by the Food and Drug Administration (FDA). These products are not meant to diagnose‚ treat or cure any disease or medical condition. Please consult your doctor before starting any exercise or nutritional supplement program or before using these or any product during pregnancy or if you have a serious medical condition.
Ratings and Reviews
Be the first to review this item.
Customer Questions and Answers
Please ask any questions you may have about this specific product in the field below.
Your question(s) and our corresponding answer(s) will not be confidential and will be posted publically on this specific product page.
Additionally, PureFormulas is unable to directly recommend products in relation to specific health conditions. Please contact your trusted healthcare practitioner for direct product recommendations.
If you have any general questions regarding orders or our policies and programs, please contact our Customer Happiness Team @ 1.800.383.6008
If you are pregnant, nursing, taking any medications or have any medical condition, consult your doctor before use. Your healthcare professional is the best source for guidance before beginning an exercise or nutritional supplement program.
Instead of considering those arguments, the Supreme Court analyzed the judgments at the circuit court and appeals court levels.
What were the lawsuits against Stannard and Cook?
Eight lawsuits were filed in February and March 2019 against the curators, Stannard and Cook.
Plaintiffs allege the alternative knee replacement surgery was marketed as viable and equally successful to traditional replacements. Individual claims were filed against Stannard and Cook relating to medical malpractice, but there also were joint claims against the pair and the curators for misrepresentation under Missouri’s Merchandising Practices Act.
University lawyers sought dismissal at the circuit court level on the misrepresentation claims, which were granted, asserting sovereign immunity, according to the Supreme Court decision. The university, as a public entity of the state, cannot be sued in state or federal court because of the sovereign immunity doctrine.
“The circuit court sustained the motions and dismissed the Curators from each of the suits with prejudice,” the Supreme Court decision stated. “These orders were in writing, signed by the judge, and denominated ‘judgments of dismissal.'”
The judgments were certified, meaning the plaintiffs could appeal.
The cases were not taken up at the appeals court level on the premise that the similar claims against Stannard and Cook were still pending at the circuit court.
The appeals court reasoned that not all of the issues with the case were resolved, so it could not yet be brought up on appeal, despite the final judgement for the curators at the circuit court.
The Supreme Court saw it differently.
“An order that ‘fully resolves at least one claim in a lawsuit and establishes all the rights and liabilities of the parties with respect to that claim’ is, in substance, a judgment,” the Supreme Court decision noted.
During the initial and repeat treatment phases of the study, hylan B IgG antibody titers were measured at baseline and throughout treatment. Only one patient exhibited a positive antibody response after treatment with hylan B. This patient experienced adverse events of injection site bruising and headache lasting 11 days and 2 days after initial treatment, respectively. These adverse events were not reported as device-related and were not considered to be associated with the increased antibody titer level. None of the other study patients developed similar increases in antibody titer levels during the initial or repeat study phases.
Side effects of Hyaluronic acid (Biojoint II) in details
Clinical Evaluation of Hyaluronic acid (Biojoint II) Gel
In a randomized, controlled clinical trial to evaluate the safety and effectiveness of Hyaluronic acid (Biojoint II) gel as a dermal filler for nasolabial folds, 261 patients 30 to 55 years of age were randomized between the treatment (Hyaluronic acid (Biojoint II)) and the control (Zyplast) implant. During the initial phase of the study, each patient was injected with the respective dermal filler in the nasolabial folds for wrinkle correction. Patients were followed for 12 weeks. Following completion of the initial phase, each of the patients who initially received Hyaluronic acid (Biojoint II) gel treatment was offered repeat treatment with Hyaluronic acid (Biojoint II) products in both nasolabial folds and evaluated for safety for an additional 4 weeks.
Initial Treatment Phase
Adverse events reported during the 12 weeks following treatment were categorized according to the reported severity.
Table 1 : Injection Procedure Related Adverse Events by Maximum Severity Occurring in > 5% of Patients [Number (%) of Patients]
Table 2: Duration of Procedure or Device Related Events Occurring in Greater thaii 5% of Patients
Device related adverse events occurred infrequently in both groups and were primarily of mild intensity; 2 patients (2%) experienced 3 events in the Hyaluronic acid (Biojoint II) group, and 9 patients (7%) experienced 14 events in the Zyplast group. The Hyaluronic acid (Biojoint II) device related adverse events were erythema, induration and pruritus.
Clinical trial adverse events unrelated to the injection procedure reported in the Hyaluronic acid (Biojoint II) treatment group occurring in greater than 1% of patients (n=133) were nasopharyngitis (5.3%), headache (4.5%), influenza (3.8%), rash (3%), conjunctivitis (1.5%), and sinusitis (1.5%).
Repeat Treatment Phase
During the initial and repeat treatment phases of the study, hylan B IgG antibody titers were measured at baseline and throughout treatment. Only one patient exhibited a positive antibody response after treatment with hylan B. This patient experienced adverse events of injection site bruising and headache lasting 11 days and 2 days after initial treatment, respectively. These adverse events were not reported as device-related and were not considered to be associated with the increased antibody titer level. None of the other study patients developed similar increases in antibody titer levels during the initial or repeat study phases.
Of the 133 patients treated with Hyaluronic acid (Biojoint II) gel during the initial phase, 96 underwent repeat treatment with Hyaluronic acid (Biojoint II) products and were followed for up to 4 weeks for safety. The types of adverse events seen after repeat treatment with Hyaluronic acid (Biojoint II) products were similar to those seen during the initial clinical evaluation. The most frequently reported adverse events included injection site erythema, bruising, swelling, pain, nodules, pruritus and tenderness. Device-related adverse events were reported in 3 patients during repeat treatment with Hyaluronic acid (Biojoint II) gel and included involuntary muscle contraction described as eye fasciculations in one patient and dizziness in another. A third patient experienced bilateral aseptic abscess formation at the site of injection, but did not develop increased hylan B antibody titers throughout either the initial or repeat phase of the study.
Surveillance outside the US
Hyaluronic acid (Biojoint II) post market safety surveillance in countries outside of the United States indicates that the most frequently reported adverse events include: injection site erythema, nodule, swelling, and induration. These adverse events are similar in frequency and duration to what has been noted during clinical trials.
Administer BiologicVET BioJOINT orally on a full stomach. For every 4.5 kg (10 lbs) of body weight, mix 1/2 scoop (2.5 g). daily with a maximum of up to 6 scoops daily. It can be added directly to your pet’s raw, wet, or dry food. For best results, daily dose should be divided between two meals. BioJOINT is intended for supplemental feeding only.
Recommended Daily Dose
| Body Weight | Daily Serving | Supply (days) – 400 g | Supply (days) – 1600 g |
| 4.5 kg (10 lb) | 1/2 scoop | 160 | 640 |
| 9 kg (20 lb) | 1 scoop | 80 | 320 |
| 13.5 kg (30 lb) | 1-1/2 scoops | 53 | 213 |
| 18 kg (40 lb) | 2 scoops | 40 | 160 |
| 22.5 kg (50 lb) | 2-1/2 scoops | 32 | 128 |
| 27 kg (60 lb) | 3 scoops | 26 | 107 |
| 31.5 kg (70 lb) | 3-1/2 scoops | 22 | 91 |
| 36 kg (80 lb) | 4 scoops | 20 | 80 |
| 40.5 kg (90 lb) | 4-1/2 scoops | 17 | 71 |
| 45 kg (100 lb) | 5 scoops | 15 | 64 |
| 49.5 kg (110 lb) | 5-1/2 scoops | 14 | 58 |
| 54 kg (120 lb)+ | 6 scoops | 13 | 53 |
Administer BiologicVET BioJOINT orally on a full stomach. For every 4.5 kg (10 lbs) of body weight, mix 1/2 scoop (2.5 g). daily with a maximum of up to 6 scoops daily. It can be added directly to your pet’s raw, wet, or dry food. For best results, daily dose should be divided between two meals. BioJOINT is intended for supplemental feeding only.